.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Federal Trade Commission
Cipla
Fish and Richardson
Deloitte
Covington
Farmers Insurance
Fuji
Argus Health

Generated: September 21, 2017

DrugPatentWatch Database Preview

Nusinersen sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for nusinersen sodium and what is the scope of nusinersen sodium freedom to operate?

Nusinersen sodium
is the generic ingredient in one branded drug marketed by Biogen Idec and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Nusinersen sodium has five hundred and forty-one patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for Generic Name: nusinersen sodium

Tradenames:1
Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list2,388
Drug Prices:see low prices
DailyMed Link:nusinersen sodium at DailyMed

Pharmacology for Ingredient: nusinersen sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: nusinersen sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,172,216 Antisense modulation of BCL-X expression► Subscribe
8,946,183Compositions and methods for modulation of SMN2 splicing► Subscribe
5,861,493 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
6,214,986 Antisense modulation of bcl-x expression► Subscribe
5,760,202 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
9,476,042Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences► Subscribe
9,107,933Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III► Subscribe
8,586,559Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences► Subscribe
6,642,367 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
6,222,025 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: nusinersen sodium

Country Document Number Estimated Expiration
Australia4383093► Subscribe
Brazil9106746► Subscribe
Australia777034► Subscribe
Australia7103398► Subscribe
European Patent Office2548560► Subscribe
Germany60143901► Subscribe
Russian Federation2566724► Subscribe
Australia4236902► Subscribe
European Patent Office0737201► Subscribe
Australia770526► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
QuintilesIMS
Covington
Accenture
Argus Health
Express Scripts
Julphar
Teva
Colorcon
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot